[
    {
	"question": "What are the rates of coronary heart disease mortality in the major statin versus control trials? (median follow-up 4.8 years)",
	"choices": [
	    "19% and 24% respectively",
	    "1.9% and 2.4% respectively",
	    "0.19% and 0.24% respectively"
	],
	"correct-answer": 1,
	"source": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)61350-5/fulltext"
    },
    {
	"question": "Which metric improved significantly in the PCSK9-inhibitor group (LDL-cholesterol levels reduced by 62%) in the ODYSSEY trial (Alirocumab)?",
	"choices": [
	    "coronary heart disease mortality",
	    "ischemic stroke",
	    "heart failure",
	    "all of the above",
	    "none of the above"
	],
	"correct-answer": 4,
	"source": "https://www.nejm.org/doi/10.1056/NEJMoa1501031"
    }
]
